News
FDA to Ask Sarepta to Halt Elevidys Shipments
Digest more
Three patients with a muscle-wasting disease died from liver failure after taking the therapy, Elevidys, or a similar ...
The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
The restructuring involves laying off about 500 employees, which is estimated to save $120 million in annual costs in 2026. This year, Sarepta expects to save about $100 million, net of estimated ...
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback